HETLIOZ

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania, Poland, United States

Active ingredients

The drug HETLIOZ contains one active pharmaceutical ingredient (API):

1 Tasimelteon UNII SHS4PU80D9 - TASIMELTEON

Tasimelteon is a circadian regulator that resets the master body clock in the suprachiasmatic nucleus (SCN). Tasimelteon acts as a Dual Melatonin Receptor Agonist (DMRA) with selective agonist activity at the MT1 and MT2 receptors. These receptors are thought to be involved in the control of circadian rhythms. It is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults. Read about Tasimelteon

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HETLIOZ Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05CH03		N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CH Melatonin receptor agonists
Discover more medicines within N05CH03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1691760
Country: IT	Agenzia del Farmaco	Identifier(s): 044394017
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1077353
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100351334
Country: US	FDA, National Drug Code	Identifier(s): 43068-220